We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences posted Q2 EPS of $0.22 versus a loss of $0.09 last year, beating estimates.
EXAS' Q2 revenues rose 16% to $811.1M, led by Cologuard and Oncotype growth.
EXAS lifts 2025 revenue forecast to $3.13-$3.17B, with the EBITDA outlook also increased.
Exact Sciences Corporation (EXAS - Free Report) reported earnings per share (EPS) of 22 cents in the second quarter of 2025 compared to the Zacks Consensus Estimate of a loss of 2 cents. The reported figure compares favorably with a loss of 9 cents in the same quarter last year.
EXAS’ Q2 Revenues
Consolidated revenues totaled $811.1 million, up 16% on a reported basis and 11% on a core revenue basis. The figure surpassed the Zacks Consensus Estimate by 4.78%.
Following the Aug. 6 announcement, shares of EXAS fell 8% to close at $43.16 on the Aug. 7 session.
Detailed Breakup of EXAS’ Q2 Revenues
Screening revenues, including laboratory service revenues from Cologuard tests and PreventionGenetics, increased 18% year over year to $811 million. Cologuard’s growth was driven by rescreens, care gap programs and improved commercial execution.
Exact Sciences Corporation Price, Consensus and EPS Surprise
Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $183 million, an increase of 9% from the year-ago quarter’s figure. This upside was propelled by the continued adoption of Oncotype DX internationally. The company also recognized $7.5 million in revenues from sublicensing TwinStrand's technology.
EXAS’ Q2 Margin Performance
Exact Sciences’ gross profit rose 15.2% year over year to $562.5 million. However, the gross margin contracted 49 basis points (bps) to 69.4% on a 17.9% rise in the cost of revenues (excluding the amortization of acquired intangibles).
Research and development expenses fell 10.1% year over year to $108.9 million. Sales and marketing expenses surged 16.8% to $247.1 million. General and administrative expenses increased 17.5% year over year to $209 million.
Overall, the adjusted operating loss totaled $2.2 million compared with the year-ago operating loss of $21.9 million.
EXAS’ Financial Update
Exact Sciences exited the second quarter with cash, cash equivalents and marketable securities of $858.4 million compared with $786 at the end of the first quarter.
Cumulative net cash provided by operating activities at the end of the second quarter was $89 million compared with $107.1 million in the year-ago period.
Exact Sciences’ 2025 Outlook
For full-year 2025, the company now anticipates total revenues between $3.130 and $3.170 billion (earlier $3.070-$3.120 billion). The Zacks Consensus Estimate is pegged at $3.15 billion.
Among these, Screening revenues are expected in the range of $2.440-$2.470 billion (previously $2.390-$2.425 billion). Precision Oncology revenues are anticipated between $690 and $700 million (earlier $680-695 million).
The adjusted EBITDA forecast has been updated to the $455-$475 million band from the earlier range of $425-$455 million.
Our Take on EXAS
Exact Sciences exited the second quarter of 2025 with better-than-expected earnings and revenues. A record 200,000 providers ordered Cologuard, with growth across all segments at record depth. The company also expanded its agreement with two of its top 10 payers to make Cologuard Plus in-network and entered an exclusive license with Freenome for a blood-based colorectal cancer screening test. It also advanced its pipeline by launching its molecular residual disease test, Oncodetect, and secured Medicare coverage.
Additionally, Exact Sciences has launched a multiyear productivity plan to bolster its operational foundation and realize meaningful cost synergies. The company has reiterated its 2027 long-term target of 15% compounded revenue growth and more than 20% adjusted EBITDA margins. It expects to deliver more than $150 million in annual savings in 2026, with more than $50 million of these savings already factored into the company’s 2025 guidance, from actions taken during the first quarter.
Meanwhile, the contraction of the gross margin in the quarter is discouraging.
EXAS’ Zacks Rank & Key Picks
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Key Takeaways
Exact Sciences Corporation (EXAS - Free Report) reported earnings per share (EPS) of 22 cents in the second quarter of 2025 compared to the Zacks Consensus Estimate of a loss of 2 cents. The reported figure compares favorably with a loss of 9 cents in the same quarter last year.
EXAS’ Q2 Revenues
Consolidated revenues totaled $811.1 million, up 16% on a reported basis and 11% on a core revenue basis. The figure surpassed the Zacks Consensus Estimate by 4.78%.
Following the Aug. 6 announcement, shares of EXAS fell 8% to close at $43.16 on the Aug. 7 session.
Detailed Breakup of EXAS’ Q2 Revenues
Screening revenues, including laboratory service revenues from Cologuard tests and PreventionGenetics, increased 18% year over year to $811 million. Cologuard’s growth was driven by rescreens, care gap programs and improved commercial execution.
Exact Sciences Corporation Price, Consensus and EPS Surprise
Exact Sciences Corporation price-consensus-eps-surprise-chart | Exact Sciences Corporation Quote
Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $183 million, an increase of 9% from the year-ago quarter’s figure. This upside was propelled by the continued adoption of Oncotype DX internationally. The company also recognized $7.5 million in revenues from sublicensing TwinStrand's technology.
EXAS’ Q2 Margin Performance
Exact Sciences’ gross profit rose 15.2% year over year to $562.5 million. However, the gross margin contracted 49 basis points (bps) to 69.4% on a 17.9% rise in the cost of revenues (excluding the amortization of acquired intangibles).
Research and development expenses fell 10.1% year over year to $108.9 million. Sales and marketing expenses surged 16.8% to $247.1 million. General and administrative expenses increased 17.5% year over year to $209 million.
Overall, the adjusted operating loss totaled $2.2 million compared with the year-ago operating loss of $21.9 million.
EXAS’ Financial Update
Exact Sciences exited the second quarter with cash, cash equivalents and marketable securities of $858.4 million compared with $786 at the end of the first quarter.
Cumulative net cash provided by operating activities at the end of the second quarter was $89 million compared with $107.1 million in the year-ago period.
Exact Sciences’ 2025 Outlook
For full-year 2025, the company now anticipates total revenues between $3.130 and $3.170 billion (earlier $3.070-$3.120 billion). The Zacks Consensus Estimate is pegged at $3.15 billion.
Among these, Screening revenues are expected in the range of $2.440-$2.470 billion (previously $2.390-$2.425 billion). Precision Oncology revenues are anticipated between $690 and $700 million (earlier $680-695 million).
The adjusted EBITDA forecast has been updated to the $455-$475 million band from the earlier range of $425-$455 million.
Our Take on EXAS
Exact Sciences exited the second quarter of 2025 with better-than-expected earnings and revenues. A record 200,000 providers ordered Cologuard, with growth across all segments at record depth. The company also expanded its agreement with two of its top 10 payers to make Cologuard Plus in-network and entered an exclusive license with Freenome for a blood-based colorectal cancer screening test. It also advanced its pipeline by launching its molecular residual disease test, Oncodetect, and secured Medicare coverage.
Additionally, Exact Sciences has launched a multiyear productivity plan to bolster its operational foundation and realize meaningful cost synergies. The company has reiterated its 2027 long-term target of 15% compounded revenue growth and more than 20% adjusted EBITDA margins. It expects to deliver more than $150 million in annual savings in 2026, with more than $50 million of these savings already factored into the company’s 2025 guidance, from actions taken during the first quarter.
Meanwhile, the contraction of the gross margin in the quarter is discouraging.
EXAS’ Zacks Rank & Key Picks
Exact Sciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , GeneDx Holdings (WGS - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite’s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry’s 18.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry’s 2.7% growth. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.